One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis
British Journal of Dermatology2013Vol. 170(2), pp. 435–444
Citations Over TimeTop 14% of 2013 papers
Kristian Reich, L. Puig, C. Paul, Knud Kragballe, TA Luger, Jo Lambert, Sergio Chimenti, Giampiero Girolomoni, Jean‐François Nicolas, E. Rizova, M. Brunori, S. Mistry, Paul Bergmans, Jane Barker, the TRANSIT Investigators, Zygmunt Adamski, G. F. Altomare, Maurizio Aricò, N. Aste, F. Aubin, M. Augustin, Fabio Ayala, H. Bachelez, E. Baran, Jane Barker, I. Belinchón, P. Berbis, Maria Grazia Bernengo, D. Bessis, M. Beylot‐Barry, F.J. Bordas Orpinell, David Burden, Matilda Bylaitė, F. Cambazard, Sara Carazo, J.M. Carrascosa, G. Carretero, R. Cerio, Sergio Chimenti, Marc David, A.‐B. Duval‐Modeste, D.J. Eedy, L. Estebaranz, Paulo Filipe, I. Flytström, Eduardo Fonseca, R. Gamanya, Pierre‐Dominique Ghislain, Alberto Giannetti, Giampiero Girolomoni, Dimitar Gospodinov, C. A. Griffiths, Jean‐Jacques Grob, G. Guillet, José Manuel Hernanz Hermosa, Matthias Hoffmann, Dimitrios Ioannidis, Arnd Jacobi, Gregor B. E. Jemec, Miroslava Kadurina, K. Kaszuba, A. Katsambas, Lajos Kemény, P. Kerkhof, K. Kragballe, N. Kuzmina, Katrina A. Lambert, Pablo Lázaro, T Lotti, TA Luger, Hagit Matz, P. Modiano, Rotraut Moessner, D. Moreno‐Ramírez, J.C. Moreno Jímenez, Nils‐Jørgen Mørk, U. Mrowietz, Ruth Murphy, Jean‐François Nicolas, Arjen Nikkels, Harley Francisco de Oliveira, A.D. Ormerod, J.‐P. Ortonne, Aurora Parodi, Rafael Pasternack, C. Paul, J. Péč, A. Peserico, Sandra Philipp, L. Piquet, P. Plantin, L. Puig, Kristian Reich, Éva Remenyik, Elisabeth Riedl, Martin Röcken, M.H.A. Rustin, Seppo Saari, P. Saïag, W. Salmhofer, D. Schadendorf, Michael Sebastian, Mária Šimaljaková, Jan C. Simon, Anna Spirén, J.F. Stalder, N.G. Stavrianeas, Michael Sticherling, T. Ternowitz, Diamant Thaçi, Bing Thio, D. Uhlig, Skaidra Valiukevičienė, F.J. Vanaclocha Sebastián, Gottfried Wozel
Abstract
Ustekinumab showed sustained 1-year efficacy and was well tolerated when initially administered according to label. Adjusting the ustekinumab dose to 90 mg may result in clinically meaningful improvement in response in patients weighing ≤ 100 kg with suboptimal initial response.
Related Papers
- → Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis(2018)13 cited
- → Ustekinumab for the treatment of Crohn’s disease(2016)10 cited
- → Ustekinumab in psoriasis: Five‐year real life experience from a single tertiary centre(2020)5 cited
- → Update on Ustekinumab for Psoriasis(2017)
- → 26440 Alternative uses of ustekinumab for nonindicated dermotologic conditions: A systematic review(2021)